

Form Title C2 Medication and Care, Adult - All Locations Order Set

Form Number 21097Bond

© 2018, Alberta Health Services, CKCM



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The license does not apply to content for which the Alberta Health Services is not the copyright owner.

To view a copy of this license, visit

https://creativecommons.org/licenses/by-nc-nd/4.0/

Disclaimer: This material is intended for use by clinicians only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.



Last Name (Legal)		First Name (Legal)		
Preferred Name	ast 🗆 First		DOB	(dd-Mon-yyyy)
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Geno			se (X)	□ Female

C2 Medication and Care, Adult All Locations Order Set

Select orders by placing a (\checkmark) in the associated box

Note: This order set is to be used in conjunction with the Care of the Imminently Dying Pathway Instructions, Initial Care Needs Assessment, and Nursing Symptom and Care Assessment and Documentation.

Admit

Admit to: Most Responsible Health Practitioner (MRHP) (in non-acute care settings, identify MRHP)

Diagnosis

Patient Care

☑ Clinical Communication: Patient has a C2 Goals of Care Designation Order (see completed Green Sleeve).

- ☑ Discontinue: previously scheduled laboratory and diagnostic investigations.
- ☑ Clinical Communication: cancel any scheduled appointments.
- □ Clinical Communication: Deactivate ICD (Implantable Cardioverter Defibrillator) as discussed with Patient/ Alternate Decision Maker (ADM).
- □ Nurse may pronounce death
- ☑ Foley Catheter: Insert PRN, only as needed for urinary retention or patient comfort,

☑ lidocaine 2% gel, apply intra-urethral once PRN, for foley catheter insertion.

☑ Notify: MRHP if symptoms are not well managed with current care and medication.

Activity

Activity as tolerated

Monitoring

Discontinue: vital signs including oximetry

Diet

As tolerated for comfort, as discussed with Patient/ADM for potential aspiration risk.

□ Regular Diet

□ Other

Clinical Communication: May have oral fluids and ice chips for comfort.

Hydration/Fluids

0.9% NaCl infusion Hypodermoclysis (HDC) SUBCUTANEOUSLY at _____ mL/hour .

Respiratory Care

□ Clinical Communication: Oxygen not required.

OR

Oxygen Therapy - Current oxygen needs for patient comfort are _____ L/min via ____

Clinical Communication - Provide fan	for dyspnea following organization's	s infection control practice guidelines.
--------------------------------------	--------------------------------------	--

Medications

Review ALL previous medication orders including diabetic management AND discontinue medications that are **NOT** related to symptom management

Subcutaneous Cannula – Insert only as needed for administration of subcutaneous medications.

Prescriber Signature	Date (dd-Mon-yyyy)	Time (hh:mm)



C2 Medication and Care, Adult All Locations Order Set

Last Name (Legal)		First Name (Legal)		
Preferred Name Last First			DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender □ Male □ Female □Non-binary/Prefer not to disclose (X) □ Unknown				

Medication continued

For comfort

□ artificial saliva gel TOPICALLY to oral mucous membrane QID for dry mouth.

- □ artificial saliva gel TOPICALLY to oral mucous membrane every 1 hour as needed (PRN) for dry mouth.
- hydroxypropylmethylcellulose 0.5% eye drops, 1 drop to each eye every 1 hour PRN while awake for dry eyes.
- macrogol propylene glycol (SECARIS®) gel INTRANASALLY to both nostrils every 4 hours PRN for dry nares.
- □ acetaminophen suppository 650 mg RECTALLY every 4 hours PRN for symptomatic fever or mild discomfort.

For pain and/or dyspnea

Review patient's current opioid history

□ opioid (complete medication name, dose, route, frequency):

□ opioid (complete medication name, dose, route, frequency):

IF no history of regular opioid use in the past four weeks:

□ morphine 2.5 mg SUBCUTANEOUSLY every 1 hour PRN for pain and/or dyspnea.

Notify MRHP if patient receives more than 3 morphine doses in 8 hours.

□ morphine 2.5 mg SUBCUTANEOUSLY every 6 hours for pain and/or dyspnea.

OR

□ HYDROmorphone 0.5 mg SUBCUTANEOUSLY every 1 hour PRN for pain and/or dyspnea. Notify MRHP if patient requires more than 3 HYDROmorphone doses in 8 hours.

□ HYDROmorphone 0.5 mg SUBCUTANEOUSLY every 6 hours for pain and/or dyspnea.

For nausea and/or vomiting

□ metoclopramide 10 mg SUBCUTANEOUSLY every 1 hour PRN for nausea and/or vomiting. Notify MRHP if patient requires more than 3 metoclopramide doses in 8 hours.

AND/OR

□ metoclopramide 10 mg SUBCUTANEOUSLY every 6 hours for nausea and/or vomiting.

OR

haloperidol 1 mg SUBCUTANEOUSLY every 1 hour PRN for nausea and/or vomiting. Notify MRHP if patient requires more than 3 haloperidol doses for nausea/vomiting and/or agitation in 8 hours.

For agitation

□ haloperidol 1 mg SUBCUTANEOUSLY every 1 hour PRN for agitation. Notify MRHP if haloperidol is ineffective after 3 consecutive doses, or if patient receives more than 3 doses for nausea/vomiting and/or agitation in 8 hours.

IF extreme agitation:

□ methotrimeprazine (NOZINAN®) 12.5 mg SUBCUTANEOUSLY every 1 hour PRN for extreme agitation. Notify MRHP if methotrimeprazine is ineffective after 3 consecutive doses.

Prescriber Signature	Date (dd-Mon-yyyy)	Time (hh:mm)



C2 Medication and Care, Adult All Locations Order Set

Last Name (Legal)		First Name (Legal)		
Preferred Name Last First			DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender □ Male □ Female □Non-binary/Prefer not to disclose (X) □ Unknown				

Medications continued

For distressing respiratory secretions

☑ Clinical Communication: Review parenteral hydration with patient/ADM and MRHP

	glycopyrrolate 0.4 mg SUBCUTANEOUSLY every 1 hour PRN for distressing respiratory secretions (less sedating effects).
Choose one	scopolamine hydrobromide 0.4 mg SUBCUTANEOUSLY every 1 hour PRN for distressing respiratory secretions.
	atropine 1% opthalmic drops, apply 2 drops BUCCALLY every 1 hour PRN for distressing respiratory secretions.

For urgent symptoms

midazolam 5 mg SUBCUTANEOUSLY 1 dose PRN and then midazolam 5 mg SUBCUTANEOUSLY every 5 minutes PRN for refractory active seizure greater than 2 minutes and/or massive distressing hemorrhage. Notify MRHP if midazolam is ineffective after 3 consecutive doses.

Consults and Referrals

Consult Palliative Care for complex symptom management and support.

Other Orders (For medication orders include: complete medication name, dose, route, frequency):					
□					
□					
□					
□					
Discontinue the following:					
Review ALL previous medication orders including diabetic management AND discontinue medications that are NOT related to symptom management					
□					
□					
Prescriber Signature	Date (dd-Mon-yyyy)	Time (hh:mm)			